ImmunoCellular Therapeutics to Hold Investor Conference Call

LOS ANGELES--(Business Wire)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) ("IMUC") announced
today that it will be holding an investor telephone conference call to
discuss its new agreement to acquire a monoclonal antibody technology
that was reported in a press release by IMUC earlier today and to
update investors on IMUC's other activities. The conference call will
be held at 7:30 a.m. PST on Thursday, November 29, 2007. The call-in
number for U.S. and Canadian investors will be 888-677-5725, and for
other international investors, the call-in number will be
210-839-8725. The passcode for both numbers will be IMUC.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles, California-based development stage company
that will seek to develop cellular therapies for the treatment of
brain and other cancers as well as neurodegenerative disorders. IMUC's
initial focus has been on a dendritic cell-based vaccine for treating
brain tumors, with a Phase I trial for its lead vaccine product
candidate having commenced in May 2007.

ImmunoCellular Therapeutics, Ltd.
Dr. John Yu, Chairman of the Board, (310) 423-0845

Copyright Business Wire 2007